Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens
BOSTON, MA and GERMANTOWN, MD – January 10, 2017 – ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the
View HTML
Toggle Summary ZIOPHARM Initiates Collaborative Research Agreement with Southern Research Institute
Option on Novel IPM Analogs
View HTML
Toggle Summary -- ZIOPHARM Oncology to Present at the 8th Annual BIO Investor Forum --
NEW YORK, Oct 22, 2009 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the 8 th Annual BIO Investor Forum on Thursday, October 29, 2009 at 10:00 am PT at the Palace Hotel in San Francisco, CA. Dr.
View HTML
Toggle Summary -- ZIOPHARM Oncology to Present at Upcoming Investor Conferences --
NEW YORK, Jun 02, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will present at the following investor conferences on Wednesday June 9, 2010: 9 th Annual Needham Healthcare Conference New York, NY 10:40 a.m. ET Jefferies 2010 Global Life Sciences Conference
View HTML
Toggle Summary A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children
  ZIOPHARM Oncology is pleased to share a story from the Ann & Robert H. Lurie Children's Hospital in Chicago on the Ad-RTS-hIL-12 plus veledimex clinical trial for pediatric patients with brain cancer. As we announced last week, Stewart Goldman, M.D., Division Head Hematology-Oncology,
View HTML
Toggle Summary Clinical and Preclinical Data for Oral Indibulin (ZIO-301) Presented at AACR/NCI/EORTC Conference
Unique Targeting Mechanism; Translation to Early Clinical Activity without Neurotoxicity
View HTML
Toggle Summary Darinaparsin Data Presented at AACR
<b>-- Data Highlights Differential Molecular Mechanisms --</b> <br />
View HTML
Toggle Summary Data From Ongoing Hematological Trials With Darinaparsin Presented at European College of Clinical Oncology Annual Meeting
BARCELONA, Spain, Sep 25, 2007 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of data from ongoing clinical trials of darinaparsin (ZIO-101) to treat advanced hematological malignancies. The data were presented yesterday at the 14th Annual European
View HTML
Toggle Summary Dr. Lewis to Participate as Chairman and Invited Lecturer at the 2nd Annual International Conference on Drug Discovery & Therapy, Dubai, UAE
NEW YORK, Jan 27, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, has been invited to participate at the 2 nd International Conference on Drug Discovery and Therapy in Dubai, United Arab Emirates as: Chairman of
View HTML
Toggle Summary Dr. Lewis to Participate in the Inaugural University College London UCL Finance Conference
NEW YORK, Feb 08, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, has been invited to present at the Inaugural UCL One Day Finance Conference to be held on February 15 th .
View HTML